UA8967

UA8967 (72 h) inhibits growth of MiaPaCa-2, Panc-1, BxPC3, CF-PAC1, AsPC1, T3M4, HCT-116 DPC4^(+/+), HCT-116 DPC4^(−/−), and HPDE-6 cells with IC₅₀ values ranging from 12-61 μM after 72 h, with 4.75-fold greater potency in HCT-116 DPC4^(−/−) cells compared to HCT-116 DPC4^(+/+) cells^[1].
UA8967 (72 h) does not selectively inhibit DNA, RNA, or protein synthesis in MiaPaCa-2 cells, with IC₅₀ values of 40 μM, 40 μM, and 28 μM respectively after 72 h, matching its growth inhibitory potency^[1].
UA8967 (0-50 μM; 24-72 h) causes a small accumulation of HCT-116 DPC4^+/+ and HCT-116 DPC4^−/− cells in G₀/G₁ phase and a reduction in S-phase cells after 24-48 h, with a more pronounced, dose-dependent S-phase reduction in HCT-116 DPC4^−/− cells that persists at 72 h^[1].
UA8967 (up to 100 μM; 24 h) induces less than 20% non-apoptotic, non-necrotic cell death in HCT-116 DPC4^(+/+) and HCT-116 DPC4^(−/−) cells at concentrations up to 100 μM after 24 h, with no caspase activation involved^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.